Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this ...

众多试验已证实了钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂的肾脏保护作用，但其在晚期慢性肾脏病（CKD，定义为 估计肾小球滤过率 eGFR < 30 mL/min/1.73 ㎡）患者的有效性和安全性尚未得到充分研究。

Comparison of eGFR change rates before and after renal internal medical referral. Before the referral (left orange), the ...

Chronic Kidney Disease (CKD) affects approximately 15% of U.S. adults and as many as 9 in 10 with CKD are unaware they have ...

The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...